The U.S. pharmaceutical industry witnessed various achievements in vaccines, cancer treatments, and other transformative drugs in the past year. While still performing below the index, the major success by Novo Nordisk with their semaglutide drugs Ozempic, Wegovy, and Rybelsus could trigger more innovations in what can be considered a high-risk area for investment, but has large patient populations.
Our patent landscape report focuses on the analysis of U.S. patents and patent applications (PPAs) relating to pharmaceuticals that were published in 2023. The search resulted in a dataset of 21,235 US PPAs. In our analysis, we focused on the top diseases and drug targets, and zeroed in on the top 10 patent applicants in the pharmaceutical space and featured some of their key patent applications for 2023. Diabetes, respiratory diseases and cancer are the top areas in innovation. The University of California, Roche, INSERM, Novartis, and Sanofi are among the leading patent applicants in the U.S. (based on number of patent filings published). Download our U.S. Pharmaceuticals Patent Landscape Report for free.
